{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:00:52Z","timestamp":1791237652866,"version":"4.1.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2020.12.017","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T21:37:58Z","timestamp":1611265078000},"page":"168-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7622-6303","authenticated-orcid":false,"given":"Niklas W.","family":"Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5506-1319","authenticated-orcid":false,"given":"Claus","family":"Zachariae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B.","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2020.12.017_bib1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaad.2020.04.058","article-title":"Cutaneous adverse reactions to anti-PD-1 treatment\u2013a systematic review","volume":"83","author":"Simonsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.12.017_bib2","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1111\/1346-8138.15316","article-title":"Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab","volume":"47","author":"Ogawa-Momohara","year":"2020","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.ejca.2020.12.017_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0961203309106176","article-title":"Drug-induced lupus: an update on its dermatologic aspects","volume":"18","author":"Marzano","year":"2009","journal-title":"Lupus"},{"issue":"26","key":"10.1016\/j.ejca.2020.12.017_bib4","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.1073\/pnas.1201131109","article-title":"Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in\u00a0vivo","volume":"109","author":"Gotot","year":"2012","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"2","key":"10.1016\/j.ejca.2020.12.017_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.ejca.2020.12.017_bib6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ng1020","article-title":"A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans","volume":"32","author":"Prokunina","year":"2002","journal-title":"Nat Genet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:17Z","timestamp":1760733077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920314428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":6,"alternative-id":["S0959804920314428"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}